A Randomized, Double-Blind, Single Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety of PT001, PT003, PT005 Administered Individually and PT001 + PT005 Delivered Together in Separate Inhalers in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Formoterol/glycopyrrolate (Primary) ; Formoterol; Glycopyrrolate
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Pearl Therapeutics
- 19 May 2010 Results were presented at the 106th International Conference of the American Thoracic Society.
- 19 May 2010 Results presented at the annual meeting of the American Thoracic Society.
- 18 May 2010 Safety and pharmacokinetic data reported at ATS, according to a Pearl Therapetuics media release.